Eli Lilly stock jumps 10% on annual guidance hike, strong Q2 top and bottom line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Eli Lilly (LLY) PT Raised to $1,150 at BofA Securities
August 9, 2024 5:56 AM EDTBofA Securities analyst Geoff Meacham raised the price target on Eli Lilly (NYSE: LLY) to $1,150.00 (from $1,000.00) while maintaining a Buy rating.
The analyst comments "LLY shares traded with strength today (+9.5%; DRG index: +4%) following the continued outperformance from Lillys incretin portfolio, including Mounjaro (Type 2 diabetes) and Zepbound (obesity). Importantly, given managements... More
Eli Lilly & Co. (LLY) Tops Q2 EPS by $1.17, Beats on Revenue; Offers Upbeat FY24 Guidance
August 8, 2024 6:47 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $3.92, $1.17 better than the analyst estimate of $2.75. Revenue for the quarter came in at $11.3 billion versus the consensus estimate of $10 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2024 EPS of $16.10-$16.60, versus the... More
